Regeneron Shares Dive Nearly 9% After Mixed COPD Drug Trial Results: What Traders Need to Know

In a surprising turn of events, shares of Regeneron Pharmaceuticals (NASDAQ: REGN) plummeted by nearly 9% in pre-market trading as the company released mixed results from its late-stage trial of an experimental treatment for chronic obstructive pulmonary disease (COPD), often referred to as "smoker's lung." This development has raised eyebrows among investors who had high hopes for the drug, itepekimab.

Alongside its partner, Sanofi (NASDAQ: SNY), Regeneron previously projected that itepekimab could yield peak sales of up to $5 billion, aiming to treat a larger patient demographic than its existing blockbuster, Dupixent, which is also indicated for COPD. However, the latest trial results may force a reevaluation of those optimistic projections.

The drug indeed demonstrated effectiveness in reducing flare-ups of COPD in one study, cutting down exacerbations by 27% compared to a placebo over 52 weeks in a trial with 1,127 participants. Yet, an additional study, which had fewer former smokers, fell short of meeting its objectives despite earlier signs of promise.

Analysts appear to be pessimistic about the outlook for this drug. Emily Field from Barclays voiced that, considering the mixed outcomes, physicians are likely to continue preferring Dupixent as their first treatment choice. Similarly, J.P. Morgan's Richard Vosser indicated that, under these circumstances, gaining regulatory approval for itepekimab might not be straightforward.

The results prompted at least three analysts to suggest that further trials may be necessary to firm up the drug's credentials for approval. This uncertainty adds another layer of complexity for traders considering their positions in Regeneron.

In terms of valuation, Regeneron's price-to-earnings ratio stands at 16.15, which is higher than that of both Gilead Sciences (NASDAQ: GILD) at 13.62 and Bristol Myers Squibb (NYSE: BMY) at 7.29. Currently trading at around $549.69, Regeneron has experienced a drop of approximately 15% this year, which may further temper investor enthusiasm.

As this situation unfolds, stock traders need to stay alert to the implications of these mixed results. The pharmaceutical market is notorious for its volatility, especially when trial results conflict with expectations. In investing, as in life, it's often wise to expect the unexpected-whether it's a hit drug or an unexpected drop on the stock ticker.